Update on antiangiogenic treatment of advanced non-small cell lung cancer (NSCLC)

Targeted Oncology

Volumn 8, Issue 1, 2013, Pages 15-26

  Schmid Bindert, Gerald ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Antiangiogenics; Bevacizumab; Non small cell lung cancer; TKI; VEGF

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEMCITABINE; PACLITAXEL; PEMETREXED; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; RAMUCIRUMAB; VASCULOTROPIN;

ADJUVANT THERAPY; ADVANCED CANCER; AGING; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GENE MUTATION; HUMAN; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SURVIVAL TIME;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; HUMANS; LUNG NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84874929632     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-013-0261-1     Document Type: Review

References (49)

1. Braghiroli MI, Sabbaga J, Hoff PM (2012) Bevacizumab: overview of the literature. Expert Rev Anticancer Ther 12:567-580
2. Hoff PM, Machado KK (2012) Role of angiogenesis in the pathogenesis of cancer. Cancer Treat Rev 38:825-833
3. Fontanini G, Boldrini L, Chine S, Pisaturo F, Basolo F et al (1999) Expression of vascular endothelial growth factor mRNA in non-small-cell lung carcinomas. Br J Cancer 79:363-369
4. Stefanou D, Batistatou A, Arkoumani E, Ntzani E, Agnantis NJ (2004) Expression of vascular endothelial growth factor (VEGF) and association with microvessel density in small-cell and non-small-cell lung carcinomas. Histol Histopathol 19:37-42
5. O'Byrne KJ, Koukourakis MI, Giatromanolaki A, Cox G, Turley H et al (2000) Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer 82:1427-1432
6. Han H, Silverman JF, Santucci TS, Macherey RS, d'Amato TA et al (2001) Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol 8:72-79
7. Yuan A, Yu CJ, Kuo SH, Chen WJ, Lin FY et al (2001) Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. J Clin Oncol 19:432-441
8. Kim KJ, Li B, Winer J, Armanini M, Gillett N et al (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841-844
9. Konno H, Arai T, Tanaka T, Baba M, Matsumoto K et al (1998) Antitumor effect of a neutralizing antibody to vascular endothelial growth factor on liver metastasis of endocrine neoplasm. Jpn J Cancer Res 89:933-939
10. Ellis LM (2006) Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer. Semin Oncol 33:S1-7
11. Reck MG, VA; Juhasz, E;Szima, B; Orlov, S; Yu, C; Pallaud, C; Scherer, SJ; Archer, V; Mok, TSK (2012) Tumour biomarker and plasma time course data from Abigail, a phase II study of 1st-line bevacizumab + chemotherapy in advanced non-squamous non-small-cell lung cancer (ns-NSCLC). Ann Oncol 37th ESMO Conference: Abstract 1236PD.
12. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ et al (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22:2184-2191
13. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550
14. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V et al (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 27:1227-1234
15. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V et al (2010) Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 21:1804-1809
16. Sandler A, Yi J, Dahlberg S, Kolb MM, Wang L et al (2010) Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer. J Thorac Oncol 5:1416-1423
17. Thomas MR, A; Fischer, J.R.; Andreas, S; Kortsik, C; Grah, C; Serke, MH; von Eiff, M; Witt, C; Kollmeier, J; Müller, E; Müller, L; Schenk, M; Heine, R; Behringer, DM; Schroeder, M; Reinmuth, N; Schnabel, P; Acker, T; Wolf, TM (2011) Innovations: Randomized phase II trial of erlotinib (E)/bevacizumab (B) compared with cisplatin (P)/gemcitabine (G) plus B in first-line treatment of advanced nonsquamous (NS) non-small cell lung cancer (NSCLC). J Clin Oncol 29, suppl.
18. Crino L, Dansin E, Garrido P, Griesinger F, Laskin J et al (2010) Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol 11:733-740
19. Peters SA AA, Gridelli C, Reck M, Kerr K, Felip E (2012) Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(supplement 7):vii56-vii64
20. Lopez-Chavez A, Young T, Fages S, Leon L, Schiller JH et al (2012) Bevacizumab maintenance in patients with advanced non-small-cell lung cancer, clinical patterns, and outcomes in the eastern cooperative oncology group 4599 study: results of an exploratory analysis. J Thorac Oncol 7:1707-1712
21. Dansin E, Cinieri S, Garrido P, Griesinger F, Isla D et al (2012) MO19390 (SAiL): bleeding events in a phase IV study of first-line bevacizumab with chemotherapy in patients with advanced non-squamous NSCLC. Lung Cancer 76:373-379
22. Lynch TJ, M; Spigel, DR; Wozniak, A; Leon, L; Fish, S; Flick, ED; Dalal, D; Kosty, MP (2012) Cumulative exposure to bevacizumab (BV) after disease progression (PD) correlates with survival in non-small cell lung cancer (NSCLC): a time-dependent analysis of the ARIES observational cohort study. Ann Oncol 37th ESMO Conference.
23. Nadler E, Yu E, Ravelo A, Sing A, Forsyth M et al (2011) Bevacizumab treatment to progression after chemotherapy: outcomes from a U.S. community practice network. Oncologist 16:486-496
24. Barlesi FdC, J; Dvornichenko, V; Kim, JH; Pazzola, A; Rittmeyer, A; Vikström, A; Mitchell, L; Wong, EK; Gorbunova, V (2011) AVAPERL (MO22089): Final efficacy outcomes for patients with advanced nonsquamous non-small cell lung cancer randomized to continuation maintenance with bevacizumab or bevacizumab + pemetrexed after first-line bevacizumab-cisplatin + pemetrexed treatment. ELCC 2011.
25. Ahn MG, R; Mezger, J (2011) AVAPERL (MO22089): Final safety of maintenance bevacizmab +/- pemetrexed in patients with advanced non-squamous non-small cell lung cancer after first-line bevacizumab-cisplatin-pemetrexed treatment. EMCC 201.
26. Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL et al (2012) Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol 13:247-255
27. Leighl NB, Zatloukal P, Mezger J, Ramlau R, Moore N et al (2010) Efficacy and safety of bevacizumab-based therapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer in the phase III BO17704 study (AVAiL). J Thorac Oncol 5:1970-1976
28. Laskin J, Crino L, Felip E, Franke F, Gorbunova V et al (2012) Safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer: safety of avastin in lung trial (MO19390). J Thorac Oncol 7:203-211
29. Wozniak Aa, J; Jahanzeb, M; Kosty, MP; Vidaver, R; Beatty, S; Teng, S; Flick, ED; Sing, A; Lynch, TJ (2010) Clinical outcomes (CO) for special populations of patients (pts) with advanced non-small cell lung cancer (NSCLC): results from ARIES, a bevacizumab (BV) observational cohort study (OCS). J Clin Oncol 28:15s
30. Besse B, Lasserre SF, Compton P, Huang J, Augustus S et al (2010) Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res 16:269-278
31. Patel JD, Bonomi P, Socinski MA, Govindan R, Hong S et al (2009) Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. Clin Lung Cancer 10:252-256
32. Patel JS et al (2012) A randomized, open-label, phase 3, superiority study of pemetrexed (Pem)+carboplatin (Cb)+bevacizumab (B) followed by maintenance Pem+B versus paclitaxel (Pac)+Cb+B followed by maintenance B in patients (pts) with stage IIIB or IV non-squamous non-small cell lung cancer (NS-NSCLC). J Thorac Oncol 7:S336
33. Ramalingam S (2012) Bevacizumab or pemetrexed disodium alone or in combination after induction therapy in treating patients with advanced non-squamous non-small cell lung cancer. NCT01107626, clinicaltrials.gov
34. Zinner RG, Saxman SB, Peng G, Monberg MJ, Ortuzar WI (2010) Treatment rationale and study design for a randomized trial of pemetrexed/carboplatin followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with advanced non-small-cell lung cancer of nonsquamous histology. Clin Lung Cancer 11:352-357
35. Gridelli C, Bennouna J, de Castro J, Dingemans AM, Griesinger F et al (2011) Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rationale and protocol dynamics of the AvaALL (MO22097) trial. Clin Lung Cancer 12:407-411
36. Arnold DA, T; Bennouna, J; Sastre, J; Osterlund, PJ; Greil, R; Van Cutsem, E; Von Moos, IR; Reyes-Rivera, M; Bendahmane, B; Kubicka, S (2012) Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study). J Clin Oncol 30.
37. Wakelee HD, SE; Keller, SM; Gandara, DR; Graziano, SL; Leighl, NB; Adjei, AA; Schiller, JH (2011) Interim report of on-study demographics and toxicity from E1505, a phase III randomized trial of adjuvant (adj) chemotherapy (chemo) with or without bevacizumab (B) for completely resected early-stage non-small cell lung cancer (NSCLC). J Clin Oncol 29.
38. Garon EB, Cao D, Alexandris E, John WJ, Yurasov S et al (2012) A randomized, double-blind, phase III study of docetaxel and ramucirumab versus docetaxel and placebo in the treatment of stage IV non-small-cell lung cancer after disease progression after 1 previous platinum-based therapy (REVEL): treatment rationale and study design. Clin Lung Cancer 13:505-509
39. Novello SR, R; Gorbunova, VA (2011) Aflibercept in combination with do-cetaxel for second-line treatment of locally advanced or metastatic non-small-cell lung cancer (NSCLC): final results of a multinational placebo-controlled phase III trial (EFC10261-VITAL). WCLC 2011.
40. Gadgeel SM (2012) Safety profile and tolerability of antiangiogenic agents in non-small-cell lung cancer. Clin Lung Cancer 13:96-106
41. Rogosin S, Sandler AB (2012) Beyond bevacizumab: antiangiogenic agents. Clin Lung Cancer 13:326-333
42. Scagliotti GV, Vynnychenko I, Park K, Ichinose Y, Kubota K et al (2012) International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. J Clin Oncol 30:2829-2836
43. Paz-Ares LG, Biesma B, Heigener D, von Pawel J, Eisen T et al (2012) Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J Clin Oncol 30:3084-3092
44. Goss GD, Arnold A, Shepherd FA, Dediu M, Ciuleanu TE et al (2010) Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. J Clin Oncol 28:49-55
45. Reck M, Kaiser R, Eschbach C, Stefanic M, Love J et al (2011) A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. Ann Oncol 22:1374-1381
46. Lara PN Jr, Douillard JY, Nakagawa K, von Pawel J, McKeage MJ et al (2011) Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol 29:2965-2971
47. Antisoma plc. Antisoma announces outcome of ASA404 ATTRACT-2 trial [press release]. Antisoma; November 11 (2010).
48. Nichol D, Stuhlmann H (2012) EGFL7: a unique angiogenic signaling factor in vascular development and disease. Blood 119:1345-1352
49. Belalcazar A, Azana D, Perez CA, Raez LE, Santos ES (2012) Targeting the Met pathway in lung cancer. Expert Rev Anticancer Ther 12:519-528